Abstract:The authors show that GM1 induced conformational change of presenilin 1 (the catalytic subunit of γ‐secretase) into a preactivated state that is ready to accommodate the substrate, thus promoting γ‐secretase cleavage of APP without affecting other substrates. At last, reducing GM1 levels significantly decreases the amyloid plaque deposition and cognitive dysfunction via reducing γ‐secretase activity. A hallmark of Alzheimer's disease (AD) is the senile plaque, which contains β‐amyloid peptides (Aβ). Ganglioside GM1 is the most common brain ganglioside. However, the mechanism of GM1 in modulating Aβ processing is rarely known. Aβ levels are detected by using Immunohistochemistry (IHC) and enzyme‐linked immune‐sorbent assay (ELISA). Cryo‐electron microscopy (Cryo‐EM) is used to determine the structure of γ‐secretase supplemented with GM1. The levels of the cleavage of amyloid precursor protein (APP)/Cadherin/Notch1 are detected using Western blot analysis. Y maze, object translocation, and Barnes maze are performed to evaluate cognitive functions. GM1 leads to conformational change of γ‐secretase structure and specifically accelerates γ‐secretase cleavage of APP without affecting other substrates including Notch1, potentially through its interaction with the N‐terminal fragment of presenilin 1 (PS1). Reduction of GM1 levels decreases amyloid plaque deposition and improves cognitive dysfunction. This study reveals the mechanism of GM1 in Aβ generation and provides the evidence that decreasing GM1 levels represents a potential strategy in AD treatment. These results provide insights into the detailed mechanism of the effect of GM1 on PS1, representing a step toward the characterization of its novel role in the modulation of γ‐secretase activity and the pathogenesis of AD.

Secretases Related to Amyloid Precursor Protein Processing

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Functions of Amyloid Precursor Protein in Metabolic Diseases

The Release and Transmission of Amyloid Precursor Protein Via Exosomes

Advances in the β-amyloid precursor protein of Alzheimer's disease

Advances in the cell biology of the trafficking and processing of amyloid precursor protein: impact of familial Alzheimer's disease mutations

Regulation of β cleavage of amyloid precursor protein

Regulation Of Beta Cleavage Of Amyloid Precursor Protein

The Recent Updates of Therapeutic Approaches Against Aβ for the Treatment of Alzheimer's Disease

Secretase inhibitors and modulators for Alzheimer’s disease treatment

Delta- and beta- secretases crosstalk amplifies the amyloidogenic pathway in Alzheimer’s disease

A GPCR/secretase Complex Regulates Β- and Γ-Secretase Specificity for Aβ Production and Contributes to AD Pathogenesis

Modifications and Trafficking of APP in the Pathogenesis of Alzheimer's Disease

Macromolecular complex in recognition and proteolysis of amyloid precursor protein in Alzheimer's disease

Cleavage of amyloid precursor protein by an archaeal presenilin homologue PSH

Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity

Recognition of the amyloid precursor protein by human γ-secretase

Intracellular A beta and its Pathological Role in Alzheimer's Disease: Lessons from the Cellular to Animal Model

Recent Advances of γ-secretase：γ-secretase Activating Protein

Pathway-Based Analysis of Genome-Wide siRNA Screens Reveals the Regulatory Landscape of App Processing

Preferential Regulation of Γ‐Secretase‐Mediated Cleavage of APP by Ganglioside GM1 Reveals a Potential Therapeutic Target for Alzheimer's Disease